Product news

Share this article:

AstraZeneca announced that the FDA has approved Crestor (rosuvastatin calcium) as an adjunct to diet to slow the progression of atherosclerosis in patients with elevated cholesterol.

Bristol-Myers Squibb said the FDA has approved new labeling for Sprycel to include a lower recommended starting dose of 100 mg once daily and safety and efficacy data in a greater number of patients with chronic-phase chronic myeloid leukemia (CML) resistant or intolerant to prior therapy including Gleevec. The product labeling now also includes data from the first randomized trial of Sprycel and Gleevec. Sprycel is indicated for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast-phase CML with resistance or intolerance to prior therapy including Gleevec.

Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.